Clinical trials: Peripheral T-cell Lymphoma, open to volunteers
NK T-Cell Lymphoma
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens.
- Trial name
- NCT07457177
- Testing
- Golidocitinib + Pegaspargase + Anti-PD-1 mAb
- Volunteers
- 40 people
- Sponsor
- LIANG WANG
Lymph Node Cancer, Cutaneous
Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical…
- Conditions
- Lymph Node Cancer, Cutaneous, T-cell Lymphoma
- Trial name
- NCT07538960
- Where
- Costa Rica
- Volunteers
- 350 people
- Sponsor
- Caja Costarricense de Seguro Social
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
Peripheral T Cell Lymphoma
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
This study will treat patients with newly diagnosed PTCL, who have no prior systemic treatment for T-cell lymphoma. This study will assess the anti-tumor efficacy of golidocitinib using 2-year Progression-Free Survival rate as…
- Trial name
- NCT07032532
- Testing
- Golidocitinib, Golidocitinib plus CHOP
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
- Trial name
- Phase I/II (NCT06874946)
- Testing
- CD5-targeted CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Peripheral T Cell Lymphoma
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the…
- Trial name
- NCT06712173
- Testing
- linperlisib and SHR2554
- Volunteers
- 33 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Lymphoma, Hodgkin Lymphoma
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia
- Trial name
- NCT06550427
- Testing
- ctDNA analyzed by phased variant
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
NK-T-Cell Lymphoma, Extranodal
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
Extranodal natural-killer (NK)/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis. Notably, patients with advanced-stage disease or early-stage non-upper aero-digestive tract (NUAT)…
- Trial name
- NCT06953739
- Testing
- P-GEMD, P-Gemox
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.
- Trial name
- NCT07842445
- Testing
- GNTbm-38
- Volunteers
- 70 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Allo HSCT Using RIC and PTCy for Hematological Diseases
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT05805605
- Testing
- Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT06244368
- Testing
- GVM±R regimen
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
NKTCL
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural…
- Trial name
- NCT07574528
- Testing
- Sintilimab, Pegaspargase, Selinexor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
Extranodal NK/T-cell lymphoma is a rare and highly aggressive subtype of non-Hodgkin lymphoma. While the overall survival rates have improved for early-stage ENKTL patients, the prognosis for those with advanced disease remains…
- Trial name
- SPIRIT-02 (NCT06583083)
- Testing
- Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Cutaneous T-cell Lymphoma (CTCL)
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma.
- Trial name
- NCT07754890
- Testing
- golidocitinib, Chidamide
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
This open-label, multicenter Ib/II phase clinical trial investigates the safety, tolerability, and preliminary efficacy of tislezumab (anti-PD-1 monoclonal antibody), golidocitinib (JAK1/STAT3 signaling pathway inhibitor), and…
- Trial name
- NCT06966154
- Testing
- tislezumab, golidocitinib, Selinexor
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Peripheral T Cell Lymphoma
Transplantation After Complete Response In Patients With T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification.
- Trial name
- TRANSCRIPT (NCT05444712)
- Testing
- Chemotherapy + follow up, Chemotherapy + ASCT + follow up
- Where
- 48 sites in France
- Volunteers
- 204 people
- Sponsor
- Hospices Civils de Lyon
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Photopheresis in Early-stage Mycosis Fungoides
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT05680558
- Testing
- UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Columbia University
PTCL
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.
- Trial name
- NCT05967949
- Testing
- chidamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
ORR, OS
Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
In the past 10 years, there have been many effective explorations on the treatment of NK/TCL at home and abroad, which has innovated the treatment mode.
- Conditions
- ORR, OS, PFS
- Trial name
- NCT07450040
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Eye & ENT Hospital of Fudan University